Skip to main content

Table 2 Outcomes of the surgical candidates

From: Analysis of the predictive role and new proposal for surgical strategies based on the modified Tomita and Tokuhashi scoring systems for spinal metastasis

Primary malignancy Surgical treatment Morbidity (%) Mortality (%) 1YSR*,% Follow up, months†
Excisional Op Palliative Op
  Type 1 Type 2 Type 3 Type 4     
Lung 0 9 11 3 8.7 8.7 13.0 4.3 (0.7 - 20.1)
Liver 0 10 5 4 10.5 5.3 31.6 8.5 (0.6 - 45.7)
Rectum 0 7 2 0 11.1 0 0 3.3 (1.0 - 4.8)
Kidney 0 4 3 0 0 0 14.3 9.2 (5.0 - 26.2)
Prostate 0 1 5 0 50.0 0 16.7 5.4 (3.9 - 36.7)
Colon 0 3 2 0 20.0 0 80 33.4 (5.6 - 46.2)
Breast 1 4 0 0 0 0 0 4.7 (4.5 - 10.4)
MM 0 4 1 0 0 0 100 27.8 (17.5 - 53.7)
Stomach 0 3 1 0 0 0 0 4.3 (2.7 - 10.5)
Uterus 1 2 1 0 75 0 25.0 7.6 (2.1 - 40.4)
Head/Neck 1 2 1 0 50 0 50.0 26.8 (3.9 - 48.5)
GB/Biliary 0 1 1 1 66.7 33.3 0 4.5 (0.7 - 5.3)
Esophagus 0 2 1 0 33.3 0 33.3 2.3 (2.1 - 13.5)
Mediastinal 0 0 2 1 0 33.3 33.3 6.3 (0.5 - 32.3)
Lymphoma 0 1 2 0 33.3 0 66.7 60.9 (11.6 - 75.1)
MPNST 0 2 0 0 0 0 50.0 24.5 (3.1 - 45.9)
Thyroid 0 0 1 1 0 0 100 45.9 (17.1 - 74.7)
Bladder 0 0 0 1 0 0 0 2.7
Others 0 1 2 1 0 0 25.0 6.8 (2.0 - 16.5)
Total 3 56 41 12 16.1 4.5 27.7 5.9 (0.5 - 75.1)
  1. *1-year survival rate; median follow-up period with ranges; MM, multiple myeloma; GB, gall bladder; MPNST, malignant peripheral nerve sheath tumor.